

1 Perceived versus proven SARS-CoV-2 specific 2 immune responses in health care professionals

3

4 Georg M.N. Behrens^{1,2}, Anne Cossmann^{1,2}, Metodi V. Stankov^{1,2}, Torsten Witte¹,
5 Diana Ernst¹, Christine Happel^{3,4,*}, Alexandra Jablonka^{1,2,*}

6

7

8 ¹Department for Rheumatology and Clinical Immunology, Hannover Medical School, Hannover, Germany

9 ²German Center for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany

10 ³Department of Pediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover,
11 Germany

12 ⁴German Center for Lung Research, Biomedical Research in End Stage and Obstructive Lung Disease/BREATH
13 Hannover

14 *these authors contributed equally to this work

15

16

17 Corresponding author:

18 Prof. Dr. med. Georg M.N. Behrens

19 Department for Rheumatology and Clinical Immunology

20 Hannover Medical School

21 Carl-Neuberg-Straße 1

22 D - 30625 Hannover

23 Tel: +49 511 532 5337

24 Fax: +49 511 532 5324

25 behrens.georg@mh-hannover.de

26

27 **Key words:** COVID-19, SARS-CoV-2, immunoglobulin, IgG, IgA, health care worker, ELISA,
28 seroprevalence, diagnostics, health care professionals

29

30 **Abbreviations:** COVID-19: coronavirus disease 19, ELISA: Enzyme-linked Immunosorbent
31 Assay, IgG: immunoglobulin G, PCR: real-time polymerase chain reaction, SARS-CoV-2:
32 Severe acute respiratory syndrome coronavirus 2

33

34 Abstract

35 There have been concerns about high rates of thus far undiagnosed SARS-CoV-2
36 infections in the health care system. The COVID-19 Contact (CoCo) Study follows 217
37 frontline healthcare professionals at a university hospital with weekly SARS-CoV-2
38 specific serology (IgA/IgG). Study participants estimated their personal likelihood of
39 having had a SARS-CoV-2 infection with a mean of 20.9% (range 0 to 90%). In contrast,
40 anti-SARS-CoV-2-IgG prevalence was about 1-2% at baseline. Regular anti-SARS-CoV-2
41 IgG testing of health-care professionals may aid in directing resources for protective
42 measures and care of COVID-19 patients in the long run.

43

44 **Brief Report**

45

46 Despite growing access of broadly available testing systems, uncertain rates of asymptomatic
47 infections have raised concerns about a potentially high rate of thus far undiagnosed SARS-
48 CoV-2 infections, particularly in frontline medical staff (1). To prevent the breakdown of
49 health-care systems during the current pandemic, the protection of medical personnel and
50 patients from contracting a SARS-CoV-2 infection is central (2).

51

52 Consent finding for case definition, COVID-19 diagnosis in suspected cases, and scaling up
53 of suitable diagnostic systems have been challenging since the start of the pandemic. Real-
54 time polymerase chain reaction (PCR) based throat swab testing was rapidly developed and
55 has helped in ascertainment and tracking of the SARS-CoV-2 outbreak (2). However,
56 sensitivity of PCR based testing, which is thus far only applied routinely for symptomatic
57 patients, crucially depends on timing and type of respiratory sampling and led to false
58 negative rates of up to 70% during the early phase of the pandemic (3,4). Serological testing
59 for SARS-CoV-2 specific immunoglobulins (Ig) is relatively easy, inexpensive, and critical for
60 epidemiological studies. SARS-CoV-2 specific B cell responses appear to correlate to disease
61 severity with rising antibody titers typically between 5 to 10 days and fully positive rates at
62 about 18 days after symptom onset (5). As such, serological testing can be helpful in
63 suspected cases with negative PCR results and in identification of asymptomatic infections
64 (6).

65

66 We initiated the COVID-19 Contact (CoCo) study to weekly monitor SARS-CoV-2 specific
67 serology (IgA/IgG) in frontline healthcare professionals (HCP) in combination with a
68 questionnaire about respiratory symptoms and risk perception. As testing system, we
69 employed a semiquantitative ELISA [EUROIMMUN Medizinische Labordiagnostik, Lübeck,
70 Germany – CE certified version: specificity 99.0%, sensitivity 93.8% after day 20 according
71 to manufacturer (5)]. We confirmed the specificity in a set of 156 sera from non-European
72 refugees and migrants (7) collected in 2015 as negative controls (mean age 31.6 years, range
73 18 – 67 years, 78% male). All but one tested negative for SARS-CoV-2 IgG (specificity 99.3%)
74 and two out of 90 tested equivocal positive for IgA (specificity 97.8%). Serum of 18 patients
75 after recovery of PCR-confirmed COVID-19 served as positive controls or to generate a
76 standard curve (mean age 44.8 years; mean duration of symptoms 11.8 days, range 3-35 days;
77 mean time since start of symptoms 30.4 days, range 21-61 days). 16/18 tested positive (n=1
78 equivocal positive) for SARS-CoV-2 IgG (sensitivity 90%) and 15/18 positive for SARS-CoV-2
79 IgA (sensitivity 85.7%). Interestingly, the duration of symptoms as a surrogate for disease
80 severity correlated significantly with the IgG ratio (extinction of sample to calibrator ratio) of
81 the SARS-CoV-2 IgG ELISA (Figure A).

82

83 Between March 23rd and April 17th, n=217 HCP from emergency rooms, infectious and
84 pulmonary disease wards, ICUs, pediatric departments and other units involved in COVID-
85 19 patient care at our university hospital were included in the study. The mean age of
86 participants was 36.5 years (range 18 to 63 years), and 65% were female. Most of them
87 worked as physicians (53.5%), nurses (27.6%), or medical assistants (9.2%). The majority of
88 participants had direct contact to patients with infectious respiratory diseases working in the
89 emergency department (40.1%), general ward (31.8%), or outpatient departments (13.8%). At
90 baseline, 1.6% of included personnel reported to have visited regions with high SARS-CoV-2

91 prevalence as defined by the German national institute of public health (Robert Koch
92 Institute (8)), 16.1% reported to have had contact to confirmed COVID-19 cases, and more
93 than one third (39.2%) to have had contact to suspected COVID-19 cases. 45.2% of HCP
94 reported to suffer from at least one respiratory symptom of any severity, and 29.0% reported
95 to have had a respiratory infection during the past two weeks.


96
97 Upon enrollment, study participants were asked to estimate their personal likelihood of
98 having had a SARS-CoV-2 infection. Only 12% of the n=201 study participants, who
99 answered this question, rated a zero chance of having already had contracted SARS-CoV-2.
100 Strikingly, the mean percentage of self-perceived positive SARS-CoV-2 infection status was
101 as high as 20.9% (range 0 to 90%). Male participants rated their infection risk lower than
102 female participants (mean 16.2% vs. 23.7%, $F=4.4$, $p=0.02$) and older subjects reported lower
103 infection probabilities as compared to younger participants (Pearson -0.33 , $p=0.004$) (Figure
104 B). Reported contact to confirmed or suspected COVID cases did not have a significant
105 impact on perceived probability of infection.

106 In contrast to the high percentage of self-perceived SARS-CoV-2 infection, only two of n=217
107 tested frontline HCP showed a clearly positive reaction in the ELISA, and two displayed
108 equivocal positive results according to the manufacturer's interpretation. Both positive
109 results were about 20-fold lower as compared to one patient with severe COVID-19 (Figure
110 A). The majority of participants (n=214) had no evidence of anti-SARS-CoV-2-IgG. Anti-
111 SARS-CoV-2-IgA was positive/equivocal positive in n=9 and n=10 subjects respectively, and
112 combined IgG and IgA positive/equivocal positive in three subjects. Altogether, anti-SARS-
113 CoV-2-IgG prevalence was in the range of 1-2%.

114
115 Our data on SARS-CoV-2-IgG is only partially representative for our university hospital, not
116 fully representative for other clinics, and we do not know the source of infection in anti-
117 SARS-CoV-2 IgG positive HCP. However, the gap between perceived risk and evidence for
118 an infection is most likely a phenomenon in many health care settings. Additionally, we have
119 only limited information about the full validity of anti-SARS-CoV-2 serology tests for
120 screening. In a setting with low COVID-19 prevalence, the use of the spike protein S1 to
121 screen for anti-SARS-CoV-2 IgG may be suboptimal, and testing for antibodies against e.g.
122 the receptor-binding domain of SARS-CoV-2 could increase sensitivity. Interestingly, given
123 the significant association between disease severity and our anti-SARS-CoV-2-IgG in our
124 ELISA, we hypothesize that asymptomatic seroconversions could lead to numerous
125 equivocal positive ELISA results (Figure A), which still may represent neutralizing activity
126 (9). Such data may be difficult to interpret in cross-sectional studies and our longitudinal
127 study design combined with neutralization assays will be informative about the magnitude
128 of ELISA result changes over time. Finally, a matter of debate remains whether serological
129 tests can also inform about COVID-19 specific immunity. Preliminary studies in rhesus
130 macaques suggest that reinfection does not occur after survival of COVID-19, supporting the
131 notion of at least temporary immunity after primary infection (10).

132
133 Taking these limitations into account, our data points towards a currently low rate of SARS-
134 CoV-2 specific IgG in HCP in Northern Germany hospitals, where no overflow of COVID-19
135 patients has challenged the healthcare system so far and confirmed outbreaks are limited.
136 This is in stark contrast to the relatively high rate of self-estimated SARS-CoV-2 infections of
137 our hospital's frontline HCP and strikingly different from currently high infection rates in
138 medical personnel from Italian regions (1). Also, our data show that personal risk perception

139 correlates to age and sex, which should be taken into account when advising hospital staff on
140 protective measures against COVID-19. Regular anti-SARS-CoV-2 IgG testing of health-care
141 workers may aid in monitoring the pandemic, assessing the quality of immune responses,
142 and directing resources to assure COVID-19 care in the long run.
143



144 **Figure:** (A) Anti-SARS-CoV-2 IgG ELISA results. PCR-confirmed COVID-19 cases are
145 depicted as black dots, health care professionals depicted as open dots (for which symptoms
146 were not considered). The grey zone (0.8-1.1 ratio) represents the range with equivocal
147 ELISA results. (B) Differences in self perceived probability for SARS-CoV-2 infection in
148 relation to sex and age.
149
150

151 References

- 152 1. Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. *N Engl J Med*.
153 2020 Mar 18. doi: 10.1056/NEJMp2005492. [Epub ahead of print]
- 154 2. Ferioli M, Cisternino C, Leo V, Pisani L, Palange P, Nava S. Protecting healthcare workers from SARS-CoV-2 infection:
155 practical indications. *European Respiratory Review* Mar 2020, 29 (155) 200068; DOI: 10.1183/16000617.0068-2020
- 156 3. Yang Yang MY, Chenguang Shen, Fuxiang Wang, Jing Yuan, Jinxiu Li, Mingxia Zhang, Zhaoqin Wang, Li Xing, Jinli Wei,
157 Ling Peng, Gary Wong, Haixia Zheng, Mingfeng Liao, Kai Feng, Jianming Li, Qianting Yang, Juanjuan Zhao, Zheng Zhang,
158 Lei Liu, Yingxia Liu. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring
159 the viral shedding of 2019-nCoV infections. medrxiv. 2020;medrxiv.org/content/10.1101/2020.02.11.20021493v2.
- 160 4. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing in
161 Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*. 2020;200642.
- 162 5. Okba NMA et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. *Emerg Infect Dis*. 2020 Apr 8;26(7). doi:
163 10.3201/eid2607.200841
- 164 6. Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* (2020).
- 165 7. Jablonka A et al. Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in
166 Germany in 2015. *European Journal of Gastroenterology & Hepatology*. Volume 29, Number 8, August 2017, pp. 939-945(7)
- 167 8. Robert Koch Institute. Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute.
168 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-03-23-en.pdf. Access: 05/03/2020
- 169 9. Streeck H, Schulte B, Kümmerer BM, Richter E, Höller T, Fuhrmann C, Bartok E, Dolscheid R, Berger M, Wessendorf L,
170 Eschbach-Bludau M, Kellings A, Schwaiger A, Coenen M, Hoffmann P, Stoffel-Wagner B, Nöthen MM, Eis-Hübinger AM,
171 Exner M, Schmithausen RM, Schmid M, Hartmann G. Infection fatality rate of SARS-CoV-2 infection in a German
172 community with a super-spreading event.
173 https://www.ukbonn.de/C12582D3002FD21D/vwLookupDownloads/Streeck_et_al_Infection_fatality_rate_of_SARS_CoV_2_infection2.pdf/%24FILE/Streeck_et_al_Infection_fatality_rate_of_SARS_CoV_2_infection2.pdf Access: 05/05/2020
- 174 10. Linlin Bao WD, Hong Gao, Chong Xiao, Jiayi Liu, Jing Xue, Qi Lv, Jiangning Liu, Pin Yu, Yanfeng Xu, Feifei Qi, Yajin Qu,
175 Fengdi Li, Zhiguang Xiang, Haisheng Yu, Shuran Gong, Mingya Liu, Guanpeng Wang, Shunyi Wang, Zhiqi Song, Wenjie
176 Zhao, Yunlin Han, Linna Zhao, Xing Liu, Qiang Wei, Chuan Qin. Reinfection could not occur in SARS-CoV-2 infected
177 rhesus macaques. *bioRxiv*. 2020;.
178
179

180

181

182 **Ethics approval and consent to participate**

183 The here presented analyses were approved by local authorities (Data Security Management
184 and Institutional Review Board of Hannover Medical School), approval number
185 8973_BO_K_2020). Informed consent was obtained from all participants.

186 **Consent for publication**

187 Not applicable

188 **Availability of data and materials**

189 The datasets used and/or analysed during the current study are available from the
190 corresponding author on reasonable request.

191 **Competing interests**

192 AJ reports grants and personal fees from Novartis, grants and personal fees from Abbvie,
193 grants and personal fees from Gilead, personal fees from Roche, outside the submitted
194 work; TW reports grants and personal fees from Novartis, grants and personal fees from
195 Abbvie, personal fees from Gilead, personal fees from Chugai, personal fees from Sanofi-
196 Aventis, non-financial support from Aesku.Diagnostics, outside the submitted work; DE Dr.
197 Enst reports grants and personal fees from Novartis, grants and personal fees from Abbvie,
198 grants and personal fees from Gilead, personal fees from Sanofi Aventis, personal fees from
199 GSK, outside the submitted work; Other authors have nothing to disclose.

200 **Funding**

201 There has been no external funding for this project.

202 **Authors' contributions**

203 GB, CH, AJ designed and managed the project, analyzed the data and drafted the
204 manuscript. AC managed proband inclusion and designed the workflow. MS performed the
205 experiments and designed the laboratory workflow, DE and TW were involved in planning
206 and supervised the project. All authors discussed the results and approved the final
207 manuscript.

208 **Acknowledgements**

209 We thank the study site coordinators and participants of the CoCo Study group.

210